These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 23218100)

  • 1. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
    J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
    J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching antipsychotic medications: not enough, too often, or just right?
    Weiden PJ
    Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
    [No Abstract]   [Full Text] [Related]  

  • 8. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
    JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.
    Johnsen E; Kroken RA; Wentzel-Larsen T; Jørgensen HA
    BMC Psychiatry; 2010 Mar; 10():26. PubMed ID: 20334680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
    Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
    BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.
    Zhang Y; Wang Q; Reynolds GP; Yue W; Deng W; Yan H; Tan L; Wang C; Yang G; Lu T; Wang L; Zhang F; Yang J; Li K; Lv L; Tan Q; Li Y; Yu H; Zhang H; Ma X; Yang F; Li L; Chen Q; Wei W; Zhao L; Wang H; Li X; Guo W; Hu X; Tian Y; Ren H; Ma X; Coid J; Zhang D; Li T;
    J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
    Kolotkin RL; Corey-Lisle PK; Crosby RD; Kan HJ; McQuade RD
    Eur Psychiatry; 2008 Dec; 23(8):561-6. PubMed ID: 18374544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.